Cargando…
A Strategy to Select Macrocyclic Peptides Featuring Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display
[Image: see text] Macrocyclic peptides (MPs) have positioned themselves as a privileged class of compounds for the discovery of therapeutics and development of chemical probes. Aided by the development of powerful selection strategies, high-affinity binders against biomolecular targets can readily b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895403/ https://www.ncbi.nlm.nih.gov/pubmed/35171585 http://dx.doi.org/10.1021/jacs.1c12822 |
_version_ | 1784662918469517312 |
---|---|
author | Oppewal, Titia Rixt Jansen, Ivar D. Hekelaar, Johan Mayer, Clemens |
author_facet | Oppewal, Titia Rixt Jansen, Ivar D. Hekelaar, Johan Mayer, Clemens |
author_sort | Oppewal, Titia Rixt |
collection | PubMed |
description | [Image: see text] Macrocyclic peptides (MPs) have positioned themselves as a privileged class of compounds for the discovery of therapeutics and development of chemical probes. Aided by the development of powerful selection strategies, high-affinity binders against biomolecular targets can readily be elicited from massive, genetically encoded libraries by affinity selection. For example, in phage display, MPs are accessed on the surface of whole bacteriophages via disulfide formation, the use of (symmetric) crosslinkers, or the incorporation of non-canonical amino acids. To facilitate a straightforward cyclization of linear precursors with asymmetric molecular scaffolds, which are often found at the core of naturally occurring MPs, we report an efficient two-step strategy to access MPs via the programmed modification of a unique cysteine residue and an N-terminal amine. We demonstrate that this approach yields MPs featuring asymmetric cyclization units from both synthetic peptides and when linear precursors are appended onto a phage-coat protein. Finally, we showcase that our cyclization strategy is compatible with traditional phage-display protocols and enables the selection of MP binders against a model target protein from naïve libraries. By enabling the incorporation of non-peptidic moieties that (1) can serve as cyclization units, (2) provide interactions for binding, and/or (3) tailor pharmacological properties, our head-to-side-chain cyclization strategy provides access to a currently under-explored chemical space for the development of chemical probes and therapeutics. |
format | Online Article Text |
id | pubmed-8895403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-88954032022-03-07 A Strategy to Select Macrocyclic Peptides Featuring Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display Oppewal, Titia Rixt Jansen, Ivar D. Hekelaar, Johan Mayer, Clemens J Am Chem Soc [Image: see text] Macrocyclic peptides (MPs) have positioned themselves as a privileged class of compounds for the discovery of therapeutics and development of chemical probes. Aided by the development of powerful selection strategies, high-affinity binders against biomolecular targets can readily be elicited from massive, genetically encoded libraries by affinity selection. For example, in phage display, MPs are accessed on the surface of whole bacteriophages via disulfide formation, the use of (symmetric) crosslinkers, or the incorporation of non-canonical amino acids. To facilitate a straightforward cyclization of linear precursors with asymmetric molecular scaffolds, which are often found at the core of naturally occurring MPs, we report an efficient two-step strategy to access MPs via the programmed modification of a unique cysteine residue and an N-terminal amine. We demonstrate that this approach yields MPs featuring asymmetric cyclization units from both synthetic peptides and when linear precursors are appended onto a phage-coat protein. Finally, we showcase that our cyclization strategy is compatible with traditional phage-display protocols and enables the selection of MP binders against a model target protein from naïve libraries. By enabling the incorporation of non-peptidic moieties that (1) can serve as cyclization units, (2) provide interactions for binding, and/or (3) tailor pharmacological properties, our head-to-side-chain cyclization strategy provides access to a currently under-explored chemical space for the development of chemical probes and therapeutics. American Chemical Society 2022-02-16 2022-03-02 /pmc/articles/PMC8895403/ /pubmed/35171585 http://dx.doi.org/10.1021/jacs.1c12822 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Oppewal, Titia Rixt Jansen, Ivar D. Hekelaar, Johan Mayer, Clemens A Strategy to Select Macrocyclic Peptides Featuring Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title | A Strategy
to Select Macrocyclic Peptides Featuring
Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title_full | A Strategy
to Select Macrocyclic Peptides Featuring
Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title_fullStr | A Strategy
to Select Macrocyclic Peptides Featuring
Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title_full_unstemmed | A Strategy
to Select Macrocyclic Peptides Featuring
Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title_short | A Strategy
to Select Macrocyclic Peptides Featuring
Asymmetric Molecular Scaffolds as Cyclization Units by Phage Display |
title_sort | strategy
to select macrocyclic peptides featuring
asymmetric molecular scaffolds as cyclization units by phage display |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895403/ https://www.ncbi.nlm.nih.gov/pubmed/35171585 http://dx.doi.org/10.1021/jacs.1c12822 |
work_keys_str_mv | AT oppewaltitiarixt astrategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT jansenivard astrategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT hekelaarjohan astrategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT mayerclemens astrategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT oppewaltitiarixt strategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT jansenivard strategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT hekelaarjohan strategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay AT mayerclemens strategytoselectmacrocyclicpeptidesfeaturingasymmetricmolecularscaffoldsascyclizationunitsbyphagedisplay |